BioBusiness

Feliza Mirasol is the science editor for 

Articles

With financing led by OrbiMed, Novo Holdings, and Jeito Capital, Alentis Therapeutics will develop a pipeline of Claudin-1-targeted ADCs to treat solid tumors.

Alentis Therapeutics Gains $181.4 Million Funding to Advance Anti-Claudin-1 ADCs in Solid Tumors

The Novo Nordisk Foundation has committed DKK 600 million (US$87.4 million) towards the initial costs of the center housing the new supercomputer, which has the potential to accelerate drug discovery innovation.

Novo Nordisk Foundation Announces Start Up of Denmark’s First AI Supercomputer Geared to Accelerate Drug Discovery Innovation

Patrick Lavery is an Editor for the MJH Life Sciences brands 

. Previously at MJH, he filled the same role for 

The new center's design will prioritize integration of the entire supply chain, with the aim of accelerating product development and autonomous production capacity in alignment with EU priorities.

Chiesi Launches Center of Excellence in Italy for Biopharmaceutical Development and Research 

Lilly has increased its manufacturing investment for biologics in Limerick, Ireland, by $1 billion while launching its new $800 million facility in Kinsale.

Lilly Plans to Grow its Biologics Manufacturing Footprint in Ireland with $1.8 Billion Expansion

With a $15 million fund-raising goal, US Specialty Formulations plans to invest in expanding its biopharma facility in Allentown, Pa.

US Specialty Formulations Conducts $15 Million Expansion on Biopharma Operations

The new biotech company will use the Series A financing to advance the development of enhanced biologics to treat solid tumors and inflammatory and immunology diseases.

Biotech Company, Third Arc Bio, Receives $165 Million in Financing to Advance Biologic Drug Development Pipeline

BeiGene has invested $800 million into a new biologics manufacturing facility in Hopewell, NJ, which also houses its clinical R&D capabilities.

BeiGene Launches Biologics Manufacturing and Clinical R&D Facility in New Jersey

Novo Nordisk plans to invest $4.1 billion in a second fill/finish manufacturing facility in Clayton, N.C., boosting its current 2024 investments into production to $6.8 billion.

Novo Nordisk Targets $4.1 Billion Expansion of US Manufacturing Capacity 

AGC Biologics has completed an expansion at its Copenhagen, Denmark, site, which doubles its bioreactor capacity for mammalian-based cell culture.

AGC Biologics Doubles Single-Use Bioreactor Capacity with Expansion at Denmark Site

FUJIFILM Diosynth Biotechnologies CEO Lars Petersen highlights the company’s strategic goals and meeting market demand for mammalian cell culture capacity. 

Funding and Investments